<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://ro-journal.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Radiation Oncology - Latest Articles</title>
        <link>http://www.ro-journal.com</link>
        <description>The latest research articles published by Radiation Oncology</description>
        <dc:date>2010-03-18T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/23" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/22" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/21" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/20" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/19" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/18" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/17" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/16" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/15" />
                                <rdf:li rdf:resource="http://www.ro-journal.com/content/5/1/14" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.ro-journal.com/content/5/1/23">
        <title>Choline PET based dose-painting in prostate cancer - Modelling of dose effects</title>
        <description>Background:
Several randomized trials have documented the value of radiation dose escalation in patients with prostate cancer, especially in patients with intermediate risk profile. Up to now dose escalation is usually applied to the whole prostate. IMRT and related techniques currently allow for dose escalation in sub-volumes of the organ. However, the sensitivity of the imaging modality and the fact that small islands of cancer are often dispersed within the whole organ may limit these approaches with regard to a clear clinical benefit. In order to assess potential effects of a dose escalation in certain sub-volumes based on choline PET imaging a mathematical dose-response model was developed.
Methods:
Based on different assumptions for alpha/beta, gamma50, sensitivity and specificity of choline PET, the influence of the whole prostate and simultaneous integrated boost (SIB) dose on tumor control probability (TCP) was calculated. Based on the given heterogeneity of all potential variables certain representative permutations of the parameters were chosen and, subsequently, the influence on TCP was assessed.
Results:
Using schedules with 74 Gy within the whole prostate and a SIB dose of 90 Gy the TCP increase ranged from 23.1% (high detection rate of choline PET, low whole prostate dose, high gamma50 / ASTRO definition for tumor control) to 1.4% TCP gain (low sensitivity of PET, high whole prostate dose, CN + 2 definition for tumor control) or even 0% in selected cases. The corresponding initial TCP values without integrated boost ranged from 67.3% to 100%. According to a large data set of intermediate-risk prostate cancer patients the resulting TCP gains ranged from 22.2% to 10.1% (ASTRO definition) or from 13.2% to 6.0% (CN + 2 definition).DiscussionAlthough a simplified mathematical model was employed, the presented model allows for an estimation in how far given schedules are relevant for clinical practice. However, the benefit of a SIB based on choline PET seems less than intuitively expected. Only under the assumption of high detection rates and low initial TCP values the TCP gain has been shown to be relevant.
Conclusions:
Based on the employed assumptions, specific dose escalation to choline PET positive areas within the prostate may increase the local control rates. Due to the lack of exact PET sensitivity and prostate alpha/beta parameter, no firm conclusions can be made. Small variations may completely abrogate the clinical benefit of a SIB based on choline PET imaging.</description>
        <link>http://www.ro-journal.com/content/5/1/23</link>
                <dc:creator>Maximilian Niyazi</dc:creator>
                <dc:creator>Peter Bartenstein</dc:creator>
                <dc:creator>Claus Belka</dc:creator>
                <dc:creator>Ute Ganswindt</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:23</dc:source>
        <dc:date>2010-03-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-23</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>23</prism:startingPage>
        <prism:publicationDate>2010-03-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/22">
        <title>Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis</title>
        <description>Background:
Mucositis is a toxic side effect of anti-cancer treatments and is a major focus in cancer research.  Pro-inflammatory cytokines have previously been implicated in the pathophysiology of chemotherapy-induced gastrointestinal mucositis.  However, whether they play a key role in the development of radiotherapy-induced gastrointestinal mucositis is still unknown. Therefore, the aim of the present study was to characterise the expression of pro-inflammatory cytokines in the gastrointestinal tract using a rat model of fractionated radiotherapy-induced toxicity.
Methods:
Thirty six female Dark Agouti rats were randomly assigned into groups and received 2.5 Gys abdominal radiotherapy three times a week over six weeks. Real time PCR was conducted to determine the relative change in mRNA expression of pro-inflammatory cytokines IL-1beta, IL-6 and TNF in the jejunum and colon.  Protein expression of IL-1beta, IL-6 and TNF in the intestinal epithelium was investigated using qualitative immunohistochemistry.
Results:
Radiotherapy-induced sub-acute damage was associated with significantly upregulated IL-1beta, IL-6 and TNF mRNA levels in the jejunum and colon.  The majority of pro-inflammatory cytokine protein expression in the jejunum and colon exhibited minimal change following fractionated radiotherapy.
Conclusions:
Pro-inflammatory cytokines play a key role in radiotherapy-induced gastrointestinal mucositis in the sub-acute onset setting.</description>
        <link>http://www.ro-journal.com/content/5/1/22</link>
                <dc:creator>Zhi Yi Ong</dc:creator>
                <dc:creator>Rachel Gibson</dc:creator>
                <dc:creator>Joanne Bowen</dc:creator>
                <dc:creator>Andrea Stringer</dc:creator>
                <dc:creator>Jocelyn Darby</dc:creator>
                <dc:creator>Richard Logan</dc:creator>
                <dc:creator>Ann Yeoh</dc:creator>
                <dc:creator>Dorothy Keefe</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:22</dc:source>
        <dc:date>2010-03-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-22</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2010-03-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/21">
        <title>Decreased 3D observer variation with matched CT- MRI, for target delineation in Nasopharynx cancer</title>
        <description>PurposeTo determine the variation in target delineation of nasopharyngeal carcinoma and the impact of measures to minimize this variation.Materials and methodsFor ten nasopharyngeal cancer patients, ten observers each delineated the Clinical Target Volume (CTV) and the CTV elective. After 3D analysis of the delineated volumes, a second delineation was performed. This implied improved delineation instructions, a combined delineation on CT and co-registered MRI, forced use of sagittal reconstructions, and an on-line anatomical atlas.
Results:
Both for the CTV and the CTV elective delineations, the 3D SD decreased from Phase 1 to Phase 2, from 4.4 to 3.3 mm for the CTV and from 5.9 to 4.9 mm for the elective. There was an increase agreement, where the observers intended to delineate the same structure, from 36 to 64 surface % (p = 0.003) for the CTV and from 17 to 59% (p = 0.004) for the elective. The largest variations were at the caudal border of the delineations but these were smaller when an observer utilized the sagittal window. Hence, the use of sagittal side windows was enforced in the second phase and resulted in a decreased standard deviation for this area from 7.7 to 3.3 mm (p = 0.001) for the CTV and 7.9 to 5.6 mm (p = 0.03) for the CTV elective.DiscussionAttempts to decrease the variation need to be tailored to the specific causes of the variation. Use of delineation instructions multimodality imaging, the use of sagittal windows and an on-line atlas result in a higher agreement on the intended target.</description>
        <link>http://www.ro-journal.com/content/5/1/21</link>
                <dc:creator>Coen Rasch</dc:creator>
                <dc:creator>Roel Steenbakkers</dc:creator>
                <dc:creator>Isabelle Fitton</dc:creator>
                <dc:creator>Joop Duppen</dc:creator>
                <dc:creator>Peter Nowak</dc:creator>
                <dc:creator>Frank Pameijer</dc:creator>
                <dc:creator>Avraham Eisbruch</dc:creator>
                <dc:creator>Johannes Kaanders</dc:creator>
                <dc:creator>Frank Paulsen</dc:creator>
                <dc:creator>Marcel Herk</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:21</dc:source>
        <dc:date>2010-03-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-21</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2010-03-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/20">
        <title>Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome </title>
        <description>Background:
Current staging systems have limited ability to adjust optimal therapy in advanced nasopharyngeal carcinoma (NPC). This study aimed to delineate the correlation between tumor volume, treatment outcome and chemotherapy cycles in advanced NPC.
Methods:
A retrospective review of 110 patients with stage III-IV NPC was performed. All patients were treated first with neoadjuvant chemotherapy, then concurrent chemoradiation, and followed by adjuvant chemotherapy as being the definitive therapy. Gross tumor volume of primary tumor plus retropharyngeal nodes (GTVprn) was calculated to be an index of treatment outcome.
Results:
GTVprn had a close relationship with survival and recurrence in advanced NPC. Large GTVprn (&#8807;13 ml) was associated with a significantly poorer local control, lower distant metastasis-free rate, and poorer survival. In patients with GTVprn &#8807; 13 ml, overall survival was better after &#8807;4 cycles of chemotherapy than after less than 4 cycles.
Conclusions:
The incorporation of GTVprn can provide more information to adjust treatment strategy.</description>
        <link>http://www.ro-journal.com/content/5/1/20</link>
                <dc:creator>Ching-Chih Lee</dc:creator>
                <dc:creator>Tze-Ta Huang</dc:creator>
                <dc:creator>Moon-Sing Lee</dc:creator>
                <dc:creator>Shih-Hsuan Hsiao</dc:creator>
                <dc:creator>Hon-Yi Lin</dc:creator>
                <dc:creator>Yu-Chieh Su</dc:creator>
                <dc:creator>Feng-Chun Hsu</dc:creator>
                <dc:creator>Shih-Kai Hung</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:20</dc:source>
        <dc:date>2010-03-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-20</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2010-03-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/19">
        <title>Hypofractionated radiotherapy for lung tumors with online cone beam CT guidance and active breathe control </title>
        <description>Background:
To study the set-up errors, PTV margin and toxicity of cone beam CT (CBCT) guided hypofractionated radiotherapy with active breathing control (ABC) for patients with non-small cell lung cancer (NSCLC) or metastatic tumors in lung.
Methods:
32 tumors in 20 patients were treated. Based on the location of tumor, dose per fraction given to tumor was divided into three groups: 12 Gy, 8 Gy and 6 Gy. ABC is applied for every patient. During each treatment, patients receive CBCT scan for online set-up correction. The pre- and post-correction setup errors between fractions, the interfractional and intrafractional, set-up errors, PTV margin as well as toxicity are analyzed.
Results:
The pre-correction systematic and random errors in the left-right (LR), superior-inferior (SI), anterior-posterior (AP) directions were 3.7 mm and 5.3 mm, 3.1 mm and 2.1 mm, 3.7 mm and 2.8 mm, respectively, while the post-correction residual errors were 0.6 mm and 0.8 mm, 0.8 mm and 0.8 mm, 1.2 mm and 1.3 mm, respectively. There was an obvious intrafractional shift of tumor position. The pre-correction PTV margin was 9.5 mm in LR, 14.1 mm in SI and 8.2 mm in AP direction. After CBCT guided online correction, the PTV margin was markedly reduced in all three directions. The post-correction margins ranged 1.5 to 2.1 mm. The treatment was well tolerated by patients, of whom there were 4 (20%) grade1-2 acute pneumonitis, 3 (15%) grade1 acute esophagitis, 2 (10%) grade1 late pneumonitis and 1 (5%) grade 1 late esophagitis.
Conclusion:
The positioning errors for lung SBRT using ABC were significant. Online correction with CBCT image guidance should be applied to reduce setup errors and PTV margin, which may reduce radiotherapy toxicity of tissues when ABC was used.</description>
        <link>http://www.ro-journal.com/content/5/1/19</link>
                <dc:creator>Yali Shen</dc:creator>
                <dc:creator>Hong Zhang</dc:creator>
                <dc:creator>Jin Wang</dc:creator>
                <dc:creator>Renming Zhong</dc:creator>
                <dc:creator>Xiaoqin Jiang</dc:creator>
                <dc:creator>Qinfeng Xu</dc:creator>
                <dc:creator>Xin Wang</dc:creator>
                <dc:creator>Sen Bai</dc:creator>
                <dc:creator>Feng Xu</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:19</dc:source>
        <dc:date>2010-02-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-19</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2010-02-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/18">
        <title>Intensity modulated radiotherapy (IMRT) in benign giant cell tumors - a single institution case series and a short review of the literature</title>
        <description>Background:
Giant cell tumors are rare neoplasms, representing less than 5 % of all bone tumors. The vast majority of giant cell tumors occurs in extremity sites and is treated by surgery alone. However, a small percentage occurs in pelvis, spine or skull bones, where complete resection is challenging. Radiation therapy seems to be an option in these patients, despite the lack of a generally accepted dose or fractionation concept. Here we present a series of five cases treated with high dose IMRT.Patients and MethodsFrom 2000 and 2006 a total of five patients with histologically proven benign giant cell tumors have been treated with IMRT in our institution. Two patients were male, three female, and median age was 30 years (range 20 - 60). The tumor was located in the sacral region in four and in the sphenoid sinus in one patient. All patients had measurable gross disease prior to radiotherapy with a median size of 9 cm. All patients were treated with IMRT to a median total dose of 64 Gy (range 57.6 Gy to 66 Gy) in conventional fractionation.
Results:
Median follow up was 46 months ranging from 30 to 107 months. Overall survival was 100%. One patient developed local disease progression three months after radiotherapy and needed extensive surgical salvage. The remaining four patients have been locally controlled, resulting in a local control rate of 80%. We found no substantial tumor shrinkage after radiotherapy but in two patients morphological signs of extensive tumor necrosis were present on MRI scans. Decline of pain and/or neurological symptoms were seen in all four locally controlled patients. The patient who needed surgical salvage showed markedly reduced pain but developed functional deficits of bladder, rectum and lower extremity due to surgery. No severe acute or late toxicities attributable to radiation therapy were observed so far.
Conclusion:
IMRT is a feasible option in giant cells tumors not amendable to complete surgical removal. In our case series local control was achieved in four out of five patients with marked symptom relief in the majority of cases.  No severe toxicity was observed.</description>
        <link>http://www.ro-journal.com/content/5/1/18</link>
                <dc:creator>Falk Roeder</dc:creator>
                <dc:creator>Carmen Timke</dc:creator>
                <dc:creator>Felix Zwicker</dc:creator>
                <dc:creator>Christian Thieke</dc:creator>
                <dc:creator>Marc Bischof</dc:creator>
                <dc:creator>Jurgen Debus</dc:creator>
                <dc:creator>Peter Huber</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:18</dc:source>
        <dc:date>2010-02-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-18</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2010-02-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/17">
        <title>Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications </title>
        <description>Purpose: To compare target dose distribution, comformality, normal tissue avoidance, and irradiated body volume  (IBV) in 3DCRT using classic anatomical landmarks (c3DCRT), 3DCRT fitting the PTV (f3DCRT), and intensity-modulated radiation therapy (IMRT) in patients with locally advanced rectal cancer (LARC).Methods and Materials: Fifteen patients with LARC underwent c3DCRT, f3DCRT, and IMRT planning. Target definition followed the recommendations of the ICRU reports No. 50 and 62. OAR (SB and bladder) constraints were D5   50 Gy and Dmax &lt; 55 Gy. PTV dose prescription was defined as PTV95 [greater than or equal to]45 Gy and PTVmin [greater than or equal to] 35 Gy. Target coverage was evaluated with the D95, Dmin, and Dmax. Target dose distribution and comformality was evaluated with the homogeneity indices (HI) and Conformity Index (CI). Normal tissue avoidance of OAR was evaluated with  the D5 and V40. IBV at 5 Gy (V5), 10 Gy (V10), and 20 Gy (V20) were calculated.
Results:
The mean GTV95, CTV95, and PTV95 doses were significantly lower for IMRT plans. Target dose distribution was more inhomogeneous after IMRT planning and 3DCRTplans had significantly lower CI. The V40 and D5 values for OAR were significantly reduced in the IMRT plans .V5 was greater for IMRT than for f3DCRT planning (p&lt;0.05) and  V20 was smaller for IMRT plans(p&lt;0.05).
Conclusions:
IMRT planning improves target conformity and decreases irradiation of the OAR at the expense of increased target heterogeneity. IMRT planning increases the IBV at 5 Gy or less but decreases the IBV at 20 Gy or more.</description>
        <link>http://www.ro-journal.com/content/5/1/17</link>
                <dc:creator>Leire Arbea</dc:creator>
                <dc:creator>Luis Isaac Ramos</dc:creator>
                <dc:creator>Rafael Martinez-monge</dc:creator>
                <dc:creator>Marta Moreno</dc:creator>
                <dc:creator>Javier Aristu</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:17</dc:source>
        <dc:date>2010-02-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-17</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2010-02-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/16">
        <title>Cytokines levels, Severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer - a prospective pilot study</title>
        <description>Background:
The purpose of this pilot study was to detect a correlation between serum cytokine levels and severity of mucositis, necessitating installation of a percutaneous endoscopic gastrostomy tube (PEG) in head and neck (H&amp;N) cancer patients receiving combined chemo-radiation therapy.Patients and MethodsFifteen patients with H&amp;N epithelial cancer were recruited to this study. All patients received radiotherapy to the H&amp;N region, with doses ranging from 50-70 Gy. Chemotherapy with cisplatin, carboplatin, 5-fluorouracil and taxanes was given to high-risk patients, using standard chemotherapy protocols. Patients were evaluated for mucositis according to WHO common toxicity criteria, and blood samples were drawn for inflammatory (IL-1, IL-6, IL-8, TNF-&#945;) and anti-inflammatory (IL-10) cytokine levels before and during treatment.
Results:
A positive correlation was found between IL-6 serum levels and severity of mucositis and dysphagia; specifically, high IL-6 levels at week 2 were correlated with a need for PEG tube installation. A seemingly contradictory correlation was found between low IL-8 serum levels and a need for a PEG tube.
Conclusion:
These preliminary results, indicating a correlation between IL-6 and IL-8 serum levels and severity of mucositis and a need for a PEG tube installation, justify a large scale study.</description>
        <link>http://www.ro-journal.com/content/5/1/16</link>
                <dc:creator>Amichay Meirovitz</dc:creator>
                <dc:creator>Michal Kuten</dc:creator>
                <dc:creator>Salem Billan</dc:creator>
                <dc:creator>Roxolyana Abdah-Bortnyak</dc:creator>
                <dc:creator>Anat Sharon</dc:creator>
                <dc:creator>Tamar Peretz</dc:creator>
                <dc:creator>Mordechai Sela</dc:creator>
                <dc:creator>Moshe Schaffer</dc:creator>
                <dc:creator>Vivian Barak</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:16</dc:source>
        <dc:date>2010-02-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-16</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2010-02-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/15">
        <title>Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis</title>
        <description>Background:
In recent years data from both mouse models and human tumors suggest that loss of one allele of genes involved in DNA repair pathways may play a central role in genomic instability and carcinogenesis. Additionally several examples in mouse models confirmed that loss of one allele of two functionally related genes may have an additive effect on tumor development. To understand some of the mechanisms involved, we examined the role of monoallelic loss or Atm and Brca1 on cell transformation and apoptosis induced by radiation.
Methods:
Cell transformation and apoptosis were measured in mouse embryo fibroblasts (MEF) and thymocytes respectively. Combinations of wild type and hemizygous genotypes for ATM and BRCA1 were tested in various comparisons.
Results:
Haploinsufficiency of either ATM or BRCA1 resulted in an increase in the incidence of radiation-induced transformation of MEF and a corresponding decrease in the proportion of thymocytes dying an apoptotic death, compared with cells from wild-type animals. Combined haploinsufficiency for both genes resulted in an even larger effect on apoptosis.
Conclusions:
Under stress, the efficiency and capacity for DNA repair mediated by the ATM/BRCA1 cell signalling network depends on the expression levels of both proteins.</description>
        <link>http://www.ro-journal.com/content/5/1/15</link>
                <dc:creator>Fengtao Su</dc:creator>
                <dc:creator>Lubomir Smilenov</dc:creator>
                <dc:creator>Thomas Ludwig</dc:creator>
                <dc:creator>Libin Zhou</dc:creator>
                <dc:creator>Jiayun Zhu</dc:creator>
                <dc:creator>Guangming Zhou</dc:creator>
                <dc:creator>Eric Hall</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:15</dc:source>
        <dc:date>2010-02-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-15</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2010-02-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.ro-journal.com/content/5/1/14">
        <title>Neo-adjuvant chemo-radiation of rectal cancer with 
Volumetric Modulated Arc Therapy: summary of technical and dosimetric features and early clinical experience

</title>
        <description>Background:
To report about initial technical and clinical experience in preoperative radiation treatment of rectal cancer with volumetric modulated arcs with the RapidArc&#174; (RA) technology.
Methods:
Twenty-five consecutive patients (pts) were treated with RA. All showed locally advanced rectal adenocarcinoma with stage T2-T4, N0-1. Dose prescription was 44 Gy in 22 fractions (or 45 Gy in 25 fractions). Delivery was performed with single arc with a 6 MV photon beam. Twenty patients were treated preoperatively, five did not receive surgery. Twenty-three patients received concomitant chemotherapy with oral capecitabine. A comparison with a cohort of twenty patients with similar characteristics treated with conformal therapy (3DC) is presented as well.
Results:
From a dosimetric point of view, RA improved conformality of doses (CI95% = 1.1 vs. 1.4 for RA and 3DC), presented similar target coverage with lower maximum doses, significant sparing of femurs and significant reduction of integral and mean dose to healthy tissue. From the clinical point of view, surgical reports resulted in a down-staging in 41% of cases. Acute toxicity was limited to Grade 1-2 diarrhoea in 40% and Grade 3 in 8% of RA pts, 45% and 5% of 3DC pts, compatible with known effects of concomitant chemotherapy. RA treatments were performed with an average of 2.0 vs. 3.4 min of 3DC.
Conclusion:
RA proved to be a safe, qualitatively advantageous treatment modality for rectal cancer, showing some improved results in dosimetric aspects.</description>
        <link>http://www.ro-journal.com/content/5/1/14</link>
                <dc:creator>Antonella Richetti</dc:creator>
                <dc:creator>Antonella Fogliata</dc:creator>
                <dc:creator>Alessandro Clivio</dc:creator>
                <dc:creator>Giorgia Nicolini</dc:creator>
                <dc:creator>Gianfranco Pesce</dc:creator>
                <dc:creator>Emanuela Salati</dc:creator>
                <dc:creator>Eugenio Vanetti</dc:creator>
                <dc:creator>Luca Cozzi</dc:creator>
                <dc:source>Radiation Oncology 2010, 5:14</dc:source>
        <dc:date>2010-02-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1748-717X-5-14</dc:identifier>
        <prism:publicationName>Radiation Oncology</prism:publicationName>
        <prism:issn>1748-717X</prism:issn>
        <prism:volume>5</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2010-02-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
